| answer text |
<p>The Department is doing everything appropriate to prepare for leaving the European
Union. We want to reassure patients that our plans should ensure the uninterrupted
supply of medicines and medical products, including those for use in the treatment
of depression, once we have left the EU.</p><p>The Department, as part of our EU exit
preparations, is implementing a multi-layered approach to mitigate potential disruption
to supply, which consists of stockpiling where possible, securing freight capacity,
changing or clarifying regulatory requirements, procuring additional warehousing,
working closely with industry to improve trader readiness and putting in place the
National Supply Disruption Response to manage potential shortages. Further details
can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans"
target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>There
is no evidence of any supply shortages being related to leaving the European Union.
We are aware that one supplier of generic agomelatine 25mg tablets discontinued supplies
in July 2019. However, we can confirm that supplies of agomelatine 25mg tablets are
currently available from several other suppliers in volumes that are sufficient to
meet normal United Kingdom demand. All patients who require agomelatine should be
able to obtain a supply from their pharmacy.</p><p> </p>
|
|
